OWKIN

💥 Owkin K Navigator launches on the 6th of May. Our free-to-use agentic AI co-pilot for researchers across the world, to enhance the productivity of biological research and drive breakthrough discoveries. Kountdown to K begins now. Sign up here → https://lnkd.in/eY-vFAqs

🧠 New Data Alert: Glioblastoma in MOSAIC-Window 🧠 Glioblastoma is one of the most aggressive brain cancers, and new insights are urgently needed. Fresh from our glioblastoma moonshot hackathon, we’re taking the next step—making high-quality glioblastoma data available to the broader research community. Researchers can now apply for access to multimodal and spatial omics data from 10 glioblastoma patients and 15 bladder cancer patients via the European Genome-Phenome Archive (EGA). If you're a researcher in academia or industry, apply now to access this powerful dataset. 🔗 Apply here: https://lnkd.in/eB_FgHHD Gustave Roussy, CHUV | Lausanne university hospital, Universitätsklinikum Erlangen, Charité - Universitätsmedizin Berlin, University of Pittsburgh

🇬🇧 Join our Director of Commercial Strategy & Operations Antoine de Sagey and AstraZeneca’s Head of Dx Europe & Canada Thomas Di Maio on April 10 at World CB & CDx Summit Europe. Antoine and Thomas will discuss how AI diagnostics can improve patient identification, accelerate gBRCA genetic testing, and strategies to increase digital pathology adoption. Register now: https://lnkd.in/eqZVEsR3

🚀 We launch K Navigator beta at the AWS Life Sciences Symposium on May 6th in New York. K Navigator is our agentic AI co-pilot for biomedical research, allowing you to: 📑 Distil insights from 26.5M scientific articles - in natural language 🧠 Integrate prior knowledge from 17 biomedical databases 👥 Navigate and visualize multiomic patient data One platform. Many applications. Infinite possibilities. Free to use for academic researchers. Sign up here: https://lnkd.in/eY-vFAqs

We share a glimpse into our Project Closing Meeting from last September, where five centers from our network - Technical University of Munich, University of Bern, University Hospital Ramón y Cajal #IRYCIS, University Hospital Basel, and CHU de Lille - came together to discuss our joint ongoing research into prostate cancer. Hear about their experiences and insights on this groundbreaking partnership, on how we’re advancing therapies for high-risk and localized prostate cancer, leveraging AI to analyze vast datasets and design smarter, more patient-centered clinical trials.

Kountdown to K Navigator’s launch on May 6th - let us introduce the scientific literature tool, K-literature, tailored to scientific research, featuring: 📑 26.5+ million papers 🧠 Natural language input 👥 Hallucination limitation Refine your hypotheses with fast biomedical literature search. Understand the science with broad or detailed answers. Incorporate knowledge from 17 other databases. Analyse and visualize raw data with our other tools, K-Knowledge and K-Multiomics. K Navigator is free to use for academic researchers. Sign up here: https://lnkd.in/eY-vFAqs

🌐 Check out the latest from Owkin in March. Dive into this month’s top highlights from Owkinews. Discover the latest in healthcare breakthroughs and groundbreaking research, your source for all the must-know news. 📬 Stay connected, subscribe now to be part of our journey of transforming healthcare innovation.

Thank you #USCAP2025! It's been an incredible week showcasing MSIntuit® CRC and our AI next-gen approach to clinically-validated AI to power precision pathology. Some key take-aways: 🤖 Thrilling to see several new AI providers entering the field, sending strong signals for an appetite for digital adoption and unique AI use cases to accelerate the industry 🧪 Interesting takes on new lab hardware providers, and some new entrants from the Asia-pacific region 🔬 Investment in digital pathology is clearly growing signalling recognition of AI’s power to help grow market traction, with Proscia announcing their funding round to advance AI-driven pathology. Missed us at booth #800? Let's connect → https://lnkd.in/eE8SVRpC

Owkin’s Chief Diagnostics Officer Meriem Sefta features on BBC Radio 4’s Woman’s Hour today, discussing the technology-powered change coming to women’s health. Meriem spoke about how AI is changing the way we diagnose women, focusing on Owkin’s RlapsRisk® BC, Owkin's AI diagnostic to help pathologists and oncologists determine the right treatment pathway for early breast cancer patients. Listen here → https://lnkd.in/ewD-kJCd

AI is evolving at an unprecedented pace, and nowhere is this transformation more profound than in biomedical research. At Owkin, we’re committed to developing AI that not only accelerates discoveries but also contributes to the broader AI/ML research community. Over the past year, our Research & Technology team has reached key milestones in: 🔹 Advancing generalizable AI for digital pathology 🔹 Pushing the boundaries of AI-powered spatial transcriptomics 🔹 Enhancing federated learning for biomedical research 🔹 Prototyping agentic AI co-pilots to empower scientists in navigating complex data and literature We summarize these contributions in our latest blog - happy reading! https://lnkd.in/eKZ7jTfD